Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness

A full list of authors and their affiliations appears at the end of the paper.

Purpose: Several hundred genetic muscle diseases have been described, all of which are rare. Their clinical and genetic heterogeneity means that a genetic diagnosis is challenging. We established an international consortium, MYO-SEQ, to aid the work-ups of muscle disease patients and to better understand disease etiology.

Methods: Exome sequencing was applied to 1001 undiagnosed patients recruited from more than 40 neuromuscular disease referral centers; standardized phenotypic information was collected for each patient. Exomes were examined for variants in 429 genes associated with muscle conditions.

Results: We identified suspected pathogenic variants in 52% of patients across 87 genes. We detected 401 novel variants, 116 of which were recurrent. Variants in CAPN3, DYSF, ANO5, DMD, RYR1, TTN, COL6A2, and SGCA collectively accounted for over half of the solved cases; while variants in newer disease genes, such as BVES and POGLUT1, were also found. The remaining well-characterized unsolved patients (48%) need further investigation.

Conclusion: Using our unique infrastructure, we developed a pathway to expedite muscle disease diagnoses. Our data suggest that exome sequencing should be used for pathogenic variant detection in patients with suspected genetic muscle diseases, focusing first on the most common disease genes described here, and subsequently in rarer and newly characterized disease genes.

Keywords: next-generation sequencing; targeted exome analysis; neuromuscular disease; limb-girdle weakness; genetic diagnosis

INTRODUCTION

Genetic muscle diseases with limb-girdle weakness (LGW) are highly heterogeneous, rare neuromuscular disorders (NMD). In addition to the characteristic progressive pelvic and shoulder girdle muscle weakness, other manifestations may include respiratory insufficiency, cardiomyopathy, contractures, and gastrointestinal complications. Consequently, these disorders diminish an individual’s quality of life and can reduce life expectancy. There is a critical need to fully characterize disease etiology to achieve accurate diagnoses and offer appropriate genetic counseling and disease management.

Despite 535 genes known to be associated with 955 distinct NMDs, many muscle disease patients still remain genetically undiagnosed. This is partly because gene-by-gene and small panel testing strategies are usually dictated by phenotype, leaving little power for the expansion of disease associations and novel disease characterizations. An unbiased methodology has thus been sought to enhance standard clinical practices. Consistent with an increased affordability over the past decade, next-generation sequencing (NGS) technologies have been integral in the diagnosis of disorders such as mitochondrial disease among others. Large-scale NGS panels were applied to 504 Italian undiagnosed muscular dystrophy and myopathy patients, and more recently to 4655 limb-girdle muscular dystrophy (LGMD) patients in the United States. By investigating 93 and 35 NMD genes, respectively, they achieved a diagnostic rate of 43% and 27%. However, to date no study has been carried out where exome sequencing (ES) has been applied to similar limb-girdle cohorts; this allowed us not only to determine the impact that the panel size has on the detection rate, but also to interrogate the exomes beyond the known NMD genes.

We describe here the application of sequential targeted exome sequencing (TES) to a large cohort of undiagnosed patients presenting with proximal muscle weakness and/or elevated serum creatine kinase (CK) levels: the MYO-SEQ project. We established a partnership between academia, industry, and patient organizations, and developed an international network that connected over 40 specialist neuromuscular referral sites. A total of 1001 exomes were first analyzed for rare pathogenic variants in 169 common NMD genes, and then in a further 260 genes associated with rarer muscle conditions. We identify the most common muscle diseases in this population and suggest that an increased number of patients can be more rapidly tested and diagnosed through an appropriate TES approach.

MATERIALS AND METHODS

Patient recruitment
We utilized the infrastructure established by TREAT-NMD (https://treat-nmd.org/) to recruit 43 NMD referral centers
from throughout Europe and the Middle East (Figure S1). Singleton patients matching the inclusion criteria of unexplained limb-girdle weakness and/or elevated CK were included in the project. Informed consent was obtained for all patients. Anonymized clinical information was entered on the PhenoTips platform (https://phenotips.org/) using NMD-specific forms. Clinical features, histological findings, electromyography results, CK levels, mode of inheritance, and disease onset and progression were recorded using Human Phenotype Ontology terms. DNA samples were submitted to the Newcastle Medical Research Council (MRC) Centre Biobank for Neuromuscular Diseases for which ethical approval was granted by the National Research Ethics Service (NRES) Committee North East–Newcastle & North Tyneside 1 (reference 08/H0906/28).

Exome sequencing, data analysis, and interpretation
ES was performed at the Broad Institute of MIT and Harvard’s Genomics Platform (Cambridge, MA, USA) using a 38-Mb targeted Illumina exome capture, as described previously. Data were first filtered for variants in 169 NMD-causing genes (Table S1), with a minor allele frequency in the ExAC control population \(^{5}\) of \(\leq 1\%\) and a moderate to high Ensembl Variant Effect Predictor. The resulting shortlists of single-nucleotide variants (SNVs) and small insertions/deletions (indels) were examined for pathogenicity by two independent data analysts (M.B./J.D./K.J./M.M./A.T. at the John Walton Muscular Dystrophy Research Centre [JWMDRC] and L.X./E.M.E./E.V./T.M. at the Broad Institute). We deemed SNVs and indels pathogenic if they had been previously and consistently reported as pathogenic in ClinVar (two gold stars review status; https://www.ncbi.nlm.nih.gov/clinvar/) and/or published literature. In line with American College of Medical Genetics and Genomics (ACMG) guidelines, \(^{10}\) pathogenicity of novel variants was evaluated based on (1) computational data, i.e., predicted to be deleterious by all, or the majority, of the in silico tools used; (2) population data, i.e., have a frequency in the control population compatible with the variant being rare disease-causing, according to its inheritance mode; and (3) allelic data, i.e., be \textit{in trans} with a pathogenic variant; however, as phase could rarely be established for putative compound heterozygous cases we refer to these as double heterozygous. Variants of uncertain significance are not discussed here. To be considered solved, a patient was required to carry two known or suspected pathogenic variants in a recessive gene, or (at least) one known or suspected pathogenic variant in a dominant gene. By suspected pathogenic variants we refer to rare and damaging variants identified in a gene associated with a disease that matches the patients’ clinical presentation, disease onset and progression, magnetic resonance image (MRI) findings, and/or muscle histopathology. The findings were disclosed to the submitting centers in tailored reports, signposting the patients to relevant disease registries. Where necessary and possible, the suspected pathogenic variants were confirmed and segregated through Sanger sequencing, muscle biopsies further investigated, and clinical histories reassessed by the referring clinicians (Figure S2).

The remaining unsolved cases were subsequently analyzed for likely pathogenic variants in a further 260 genes (Table S2) including those associated with neuropathies, cardiomyopathies, and other phenotypes presenting with muscle weakness to identify rarer neuromuscular conditions. This extended gene list also included genes newly associated with muscle disease. ES data were also analyzed for copy-number variants (CNVs) \(^{11}\) and SMN1 exon 7 deletions \(^{12}\) (Supplementary Materials and Methods). For those cases carrying a single heterozygous pathogenic variant in the most common (exclusively recessive) genes found in our cohort (i.e., CAPN3, DYSF, ANO5, and SGCA) we further interrogated the noncoding regions of the gene captured in the ES data. In addition, for the DYSF carriers we Sanger sequenced two previously reported pathogenic intrinsic variants. \(^{13}\) Finally, one patient was also subjected to genome sequence (GS) and RNA sequencing (RNA-Seq), as described elsewhere. \(^{14}\)

RESULTS
Demographics of 1001 patients with suspected genetic muscle disease
One thousand and one patients were recruited into the MYO-SEQ project, with the majority (93%) inferred to be of European or Middle Eastern ancestry. The study cohort comprised 545 (54%) males and 456 (46%) females and originated from 972 families. Disease onset for 42% of the patients was in adulthood (Figure S3A) and the mean age at the time of recruitment was 39 years (Figure S3D). Proximal muscle weakness, either in isolation or with distal muscle weakness, affected most participants (77%; Figure S3B), while 68% of the cohort had increased serum CK levels (Figure S3C). Based on family history, 46% of patients were sporadic cases, while 14%, 7%, and 1% showed recessive, dominant, and X-linked inheritance, respectively; for the remaining 32%, no indication of inheritance pattern was stated by the referring clinician.

Initial screening detected suspected pathogenic variants in 47% of participants
Using the World Muscle Society gene table (http://www.musclegenetable.fr/) we generated a list of 169 genes known to be associated with limb-girdle muscle disease (Table S1) and initially restricted our search for likely causal variants to only these genes. As a result, 468 patients (47%) had rare known or suspected pathogenic variants across 72 genes that we considered were causal; these cases were deemed solved (Table 1, Fig. 1).

Frequency of NMD genes varied greatly in our cohort
The most common disease in our cohort was LGMD R1 calpain3-related, caused by autosomal recessive pathogenic variants in CAPN3. Variants in CAPN3 and seven other genes —DYSF, ANO5, DMD, RYRI, TTN, COL6A2, and SGCA—accounted for over half of the solved cases (\(n = 260\)). The
other 208 solved cases had suspected pathogenic variants across 64 additional genes. Importantly, we identified a stop-gain TTN founder pathogenic variant (p.[Gln35879Ter]) in 14 patients from a Serbian subpopulation. Without this variant, TTN would be outnumbered by COL6A2 and COL6A3 (collagen VI-related myopathies), SGCA (LGMD R3 α-sarcoglycan-related), and FLNC (myofibrillar myopathy 5 and distal myopathy 4). Some diseases were notably absent from our cohort; for example, no POMGnT1 (LGMD R15 POMGnT1-related) or ISPD (LGMD R20 ISPD-related) patients were identified, highlighting the extreme rarity of these diseases. When the data were stratified by sex, there appeared to be a skewed ratio of males (n = 22; 69%) to females (n = 10; 31%) harboring suspected pathogenic variants in ANO5 (p < 0.0691), confirming previously reported findings.15

**Homzygous variants associated with established autosomal dominant inheritance**

A proband from a consanguineous pedigree harbored a previously reported dominant pathogenic variant (c.476G>A p.[Arg159His]) in VCP in homogyzosity, while another proband carried a novel homozygous variant (c.1325C>G p.[Pro442Arg]) in FLNC; both genes have established autosomal dominant inheritance. In both cases, the clinical presentation was in keeping with what was expected, but at the more severe end of the spectrum with an earlier disease onset. Both sets of parents were heterozygous for the respective variants. The mother of the homozygous VCP patient remained asymptomatic at the time of examination, while the father presented with proximal weakness and atrophy of the upper and lower limbs, and rimmed vacuoles on histopathology,16 as would be expected for this previously reported dominant variant.17 On the other hand, the parents of the homozygous FLNC patient were both clinically unaffected on examination. This would suggest a different pathological mechanism for this novel FLNC variant and functional work is underway (unpublished data by University Duisburg–Essen).

**Solved rate differed with geographical location of the participating center**

When the data were stratified by geographic location, there was a clear distinction between regions with and without the infrastructure to sufficiently prescreen patients prior to submission. The detection rate for referring centers in Eastern Europe and the Middle East was as high as 95%, including, for example, 57 LGMD R1 calpain3-related and 32 LGMD R2 dysferlin-related cases. Conversely, the detection rate for Western Europe was as low as 35%, with only 23 LGMD R1 calpain3-related (p < 0.00001) and 15 LGMD R2 dysferlin-related cases (p < 0.00001), and a larger proportion of rarer genes and phenotypes (Fig. 2).

---

*Table 1 Breakdown of genes in which suspected causal variants were identified in the MYO-SEQ cohort.*

| Gene   | Number of patients | Gene Number of patients | Gene Number of patients | Gene Number of patients | Gene Number of patients |
|--------|--------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| CAPN3  | 78                 | POGlut1*                | 5                       | PYROXD1*                | 2                       | HSPB1*                | 1                       |
| RYR1   | 26                 | SCN4A                   | 5                       | SGCb                    | 2                       | HSPB8*                | 1                       |
| DYSF   | 45                 | CLCN1                   | 3                       | ACADVL                  | 1                       | INPP5K*               | 1                       |
| ANO5   | 33                 | DNM2                    | 4                       | BAG3                    | 1                       | LPIN1                 | 1                       |
| DMD    | 31                 | MYOT                    | 4                       | BVES*                   | 1                       | MATR3                 | 1                       |
| TTN    | 25                 | RAPSN                   | 4                       | CACNA1S*                | 1                       | MGME1*                | 1                       |
| COL6A2 | 17                 | DNAJB6                  | 3                       | CHRND                   | 1                       | MME*                  | 1                       |
| SGCA   | 16                 | GMPBB                   | 3                       | COL12A1                 | 1                       | MYF6                  | 1                       |
| COL6A3 | 12                 | MTM1                    | 3                       | CPT2                    | 1                       | MYH14                 | 1                       |
| FLNC   | 12                 | SER1V                   | 3                       | CRYAB                   | 1                       | NEB                   | 1                       |
| DES    | 10                 | TCAP                    | 3                       | DOK7                    | 1                       | PFKM                  | 1                       |
| GAA    | 10                 | TRAPPc11                | 3                       | DPM3                    | 1                       | PGK1                  | 1                       |
| LAMA2  | 10                 | ACTA1                   | 2                       | DYNC1H1*                | 1                       | POLG                  | 1                       |
| POMT2  | 10                 | AGL                     | 2                       | EGR2*                   | 1                       | PTPLA                 | 1                       |
| COL6A1 | 10                 | ATP2A1                  | 2                       | ETFDH                   | 1                       | SYNE2                 | 1                       |
| LMFNA  | 9                  | COLQ                    | 2                       | FKTN                    | 1                       | Tmem8C*               | 1                       |
| MYH7   | 9                  | FHL1                    | 2                       | GBE1                    | 1                       | TNNT3                 | 1                       |
| FKRP   | 8                  | PHKA1                   | 2                       | GPT1                    | 1                       | TPM2                  | 1                       |
| SGCG   | 8                  | POMK                    | 2                       | GNE                     | 1                       | TTR*                  | 1                       |
| SMCHD1 | 8                  | POMT1                   | 2                       | GYG1                    | 1                       | VCP                   | 1                       |
| TRIM32 | 7                  | PRPS1*                  | 2                       | HNRNPA1*                | 1                       | VMA21                 | 1                       |
| CAV3   | 5                  | PYGM                    | 2                       | HNRNPDL                 | 1                       |                       | 1                       |

Suspected causal variants were identified in 87 genes in 489 patients; 72 genes during the first round of analysis using a gene list of 169 neuromuscular disorder (NMD) genes, and 15 additional genes when using a gene list extended by a further 260 NMD genes.

*Fifteen additional genes identified.*
Analysis of an extended gene list increased the diagnostic yield to 49%

For the remaining unsolved cases, we extended the analysis to a total of 429 disease-causing genes (Table S2). This resulted in a 2% increase in detection rate to an overall 49% (n = 488), across 87 muscle disease–associated genes; 15 genes more than the initial analysis. These genes were associated with neuropathies (EGR2, DYNC1H1, HSPB1, HSPB8, PRPS1, and MME), multisystemic disorders presenting with muscle weakness (HNRNPA1, INPP5K, TMEM8C, and TTR), channelopathies (CACNA1S), and mitochondrial disease (MGME1), all detected in patients who had been initially clinically diagnosed as LGW (n = 12). In addition, three genes only recently associated with muscular dystrophy (BVES and POGLUT1)16,19 and myofibrillar myopathy (PYROXD1)20 were found in eight patients. Thus, after the eight most common disease genes, accounting for 25% of the full cohort, the next ten genes (COL6A3, FLNC, DES, GAA, LAMA2, POMT2, COL6A1, LMNA, MYH7, and FKRP) account for an additional 10%, followed by a very small but nonetheless meaningful increase in solved rate as very rare and/or unexpected disease genes, as well as those recently described, are detected (Table 1).

Expanding exome sequencing beyond single base pair changes and small indels increased the detection yield by a further 3%

Further to point variants and small indels, we detected suspected pathogenic CNVs in 26 (3%) patients. Of these, 17 carried copy-number zero deletions (at exon or multiexon level) in autosomal recessive genes (DYSF, SGCA, SGCB, SGCD, SGCG, and LPIN1; n = 10) and in X-linked genes (DMD, EMD, and FHL1; n = 7, all males). Eight cases carried a heterozygous CNV in combination with a suspected pathogenic SNV in the same gene and one case, presenting with a classical dominant myofibrillar myopathy phenotype,
carried a heterozygous deletion in DES. Some of these CNVs were recurring; we identified a 10.4-kb deletion in CAPN3 in five unrelated patients, and a 0.7-kb and 0.12-kb deletion in SGCD and SGCG, respectively, in two unrelated patients each (Table S3). In addition, we looked for homozygous deletions of exon 7 in SMN1, causative of spinal muscular atrophy. Such deletions were detected in five patients (0.5%), all of which were confirmed by multiplex ligation-dependent probe amplification (MLPA). Finally, through additional RNA-Seq and GS, we were able to identify an intronic change resulting in a 73-bp intron inclusion in DMD leading to a premature stop codon in one patient with a clear Becker-like phenotype and supporting family history, but with no evident causal exonic DMD variant, highlighting that strong phenotypic clues should always be followed up.

**Over 400 novel suspected pathogenic variants were identified**

In total, we identified 865 SNV and indel changes in 429 genes that were most likely to contribute to the 496 participants’ diseases. A breakdown of the genotypes and types of variants is shown in Fig. 3a, b. The 865 variants were accounted for by 520 distinct variants (Table S4); of these, 119 had been submitted to ClinVar previously, while the remaining 401 were novel and had not been yet reported at the time of the analysis (Fig. 3c). Of the novel variants, 285 were seen only once and, notably, 116 were seen multiple times in our patient population (Fig. 3d). These novel variants will be submitted to ClinVar to aid future genetic diagnoses.

**Single heterozygous pathogenic variants in the most common recessive genes account for 2.5% of the unsolved cases**

To unravel the remaining unsolved patients, we looked at those who carried single reported pathogenic variants in the four most common exclusively recessive genes found in our cohort. We found 25 (2.5%) heterozygous carriers: 13 CAPN3, 9 ANO5, 2 SGCA, and 1 DYSF. These cases were accounted for by 16 pathogenic variants: 10 CAPN3, 4 ANO5, 1 DYSF, and 1 SGCA. These variants were all more frequent in our cohort of patients than in the control population. For example, a rare SGCA variant (c.229C>T; p.[Arg77Cys]) occurred four times more frequently in the disease population ($p = 0.02$), the common Eastern European CAPN3 variant (c.550delA; p.[Thr184ArgfsTer36]) over eight times more ($p = 0.00028$), and the European founder ANO5 variant (c.191dupA; p.[Asn63fs]) almost five times more ($p = 0.00016$). This suggests that these variants are likely to play...
Fig. 3 Breakdown of the suspected pathogenic variants and genotypes in the MYO-SEQ cohort. (a) Zygosity of the solved patients’ variants (n = 506; 489 patients, 20 with an additional gene to report). (b) Type of variants suspected to be pathogenic. Initiation and stop loss occurred twice each (n = 865). (c) The 865 occurrences were accounted for by 520 distinct variants, of which 119 were reported as pathogenic in ClinVar and 401 were novel in their association to disease at the time of the analysis. (d) Of the 119 distinct variants reported in ClinVar, 70 were detected in only one individual (unique) while 49 were detected in multiple patients. Of the 401 distinct variants that were novel in their association to disease, 285 were detected in only individual cases, while 116 were detected in multiple families.
a role in disease manifestation and that a second cryptic
disease-causing variant might not have been detected by our
analysis; we therefore interrogated these carriers further by
looking into the noncoding regions present in their exome
data. We thus identified one novel 3′ UTR and two rare
CAPN3 intronic variants, one of which (c.1746-20C>G)
ocurred in three cases. Histopathological analysis showed
markedly reduced calpain3 immunostaining, suggesting that
this noncoding variant may affect splicing or protein stability.
In addition, we identified an intronic deletion
(c.585–31_585-24delTCTGCTGTA) in one of the SGCA
carriers, which results in partial expression of the α-
sarcoglycan protein.21 Conversely, none of the reported
pathogenic intronic variants in DYSF21,3 were found in the
DYSF carrier.

Many patients harbored suspected pathogenic variants in
genes associated with treatable or manageable conditions
Our study identified 64 patients (6.5%) that might benefit
from treatment or specific management options related to
their diagnosis. For example, variants in COLQ, DOK7,
GFPT1, and RAPSN—all associated with congenital myasthe-
nic syndrome (CMS)—were identified in eight patients (<1%).
We also identified ten patients (1%) with compound
heterozygous variants in GAA, associated with Pompe
disease.22 Nine patients (1%) harbored variants in either
SCN4A or CLCN1 and thus were suspected to have ion
channel disorders that could benefit from selective drug
interventions. We identified 13 female patients (1%) who
were likely to be manifesting carriers of Duchenne muscular
dystrophy, an X-linked disorder that often escapes clinical
diagnosis in females.23 Finally, we identified 24 patients (2%)
with heterozygous suspected pathogenic variants in RYR1,
which can confer susceptibility to malignant hyperthermia.

DISCUSSION
We sought to improve the diagnostic pathway of patients with
limb-girdle muscle diseases by implementing TES as a first-
pass diagnostic strategy. By focusing on 429 NMD genes
within the exome data, we solved 49% of our cohort,
comparable with equivalent NGS panel studies.6,7 A small
number of common NMD genes, namely CAPN3, DYSF,
AN05, DMD, RYR1, TTN, COL6A2, and SGCA accounted for
more than half of the solved cases. Our finding that LGMD
R1 calpain3-related was the most common LGMD in our
cohort is in agreement with other European studies.6 Standard
calpain3 immunoblot testing can only achieve a low
sensitivity,23 which could explain why a tenth of the MYO-
SEQ cohort was not diagnosed with this LGMD prior to
enrollment. Moreover, many of the calpain3-related patients
were referred from centers without the technical infrastruc-
ture to prescreen their patients.

Given the considerable phenotypic overlap and the rarity
of some of these muscle conditions, it is almost impossible for
clinicians, however expert, to individually diagnose every
disease. Some of the LGMDs, such as R15 POMGnT1-related
and R20 ISPD-related, were absent from our cohort. No SNVs
and only one CNV were identified in the SGCD gene, in
keeping with other sequencing projects from China (n =
756),24 Italy (n = 504),6 and the United States (n = 4656)7
where no SGCD variants were found. Interestingly, LGMD R6
δ-sarcoglycan–related patients accounted for >1% of the
diagnosed cases in a South American cohort (n = 2103),25
highlighting that the geography-specific prevalence of some
diseases should be considered during clinical work-ups. Per
sex bias, we corroborated previous findings that ANO5
diagnosis is more frequent in males.15 This is likely due to
the milder, sometimes asymptomatic, presentation of LGMD
R12 anoctamin5-related in females; because of this, females
can present to clinic much later in life, or not at all, skewing
the diagnostic rate in favor of males.

The relatively small benefit observed when extending the
gene list from 169 to 429 genes is in line with a panel study of
700 NMD genes where exome sequencing of the remaining
undiagnosed cases did not improve the pick-up rate for known
NMD genes.26 However, having exome data available, such as
in our study, allows for both gene discovery and data analysis
reiteration when new disease genes are characterized, neither
of which are possible even with a large NGS panel approach.
This was the case for the BVES, POGLOUTI, and PYROXDI
patients who were missed in the first round of analysis, as the
genes had not yet been described as disease-causing. By
interrogating the whole exome of the unsolved patients, we
identified and have functionally characterized two novel genes,
one associated with a rare secondary dystroglycanopathy and
the other, POIPOC3, found in three unrelated individuals,
associated with a typical LGMD phenotype.27 Two additional
novel candidate genes are under investigation and we expect
that this will only increase as the exome data of unsolved
patients are more intricately examined.

It is possible that further causative variants have not been
assigned pathogenicity due to the limitations of proband-
only analysis or that they have not been detected due to
nonuniform coverage and/or poorly designed capture baits
that might not target relevant tissue-specific exons. For
example, repeat regions in NEB or TTN are known to be
difficult to map to the genome and therefore variants in
these regions are poorly called.28 Somatic mosaicism,29
only detected by deep coverage sequencing, would also have
been missed. A further proportion of the remaining
undiagnosed cases might be caused by genetic changes in
intergenic, intronic, or regulatory regions not covered by ES.
The overrepresentation in our disease cohort of carriers of
known pathogenic variants in recessive genes likely implies
that a second cryptic variant is yet to be detected. In fact,
when interrogating these cases further we identified recurrent suspected pathogenic intronic variants and CNVs.
Otherwise, these pathogenic heterozygous variants might
act as disease modifiers, contributing to the disease severity
or progression.30

Using modified pipelines, we have identified several disease-
causing CNVs, accounting for 3% of the diagnoses. However,
more complex structural variants such as translocations and inversions, would not have been detected.\textsuperscript{31} In a similar manner, tri- and tetranucleotide expansion repeats, such as the cause of some adult onset neuromuscular conditions (e.g., myotonic dystrophy), are typically missed in standard short-read NGS data. Interestingly, four unsolved cases were reported to present with myotonia, percussion myotonia, or myotonic discharges. Other novel late-onset myopathies might be caused by similar mechanisms and long-read NGS would be needed to identify them. Digenic or non-Mendelian inheritance, such as genomic imprinting, may also account for a proportion of the undiagnosed patients\textsuperscript{32,33} and will need a different methodological and analytical strategy.

It is also possible that some of the unsolved patients may have acquired forms of muscle disease, such as acquired immune, inflammatory, noninflammatory, or even statin-induced myopathies. In fact, during the project four patients (<1\%) obtained a confirmed diagnosis of inclusion body myositis. Regular screening for anti-NT5c1A and anti-HMGCoR should provide a more realistic indication of the prevalence of these diseases in the affected population.

Over 6\% of our patients received a genetic outcome that resulted in specific monitoring and tailored treatments. For example, for the CMS patients, genetic diagnoses were vital to provide adequate treatment, as this depends on the disease subtype and causative gene. Indeed, the referring clinicians reported that these patients all showed marked improvement after appropriate treatments were commenced. The pathogenicity of the \textit{RYR1} variants could not always be fully confirmed, yet it was prudent to return these potential diagnoses to physicians to manage possible risk of malignant hyperthermia. For most of the solved cases, however, who might not benefit from specific treatment, their genetic diagnosis will nevertheless allow appropriate family planning, counseling, and monitoring of their diseases.

\textbf{MYO-SEQ} was a worldwide partnership between academia, industry, and patient organizations. Frequent communication with the referring physicians was essential for the success of the project; to reach a meaningful diagnosis, interpretation of the genetic data was always in the context of clinical, histopathological, and MRI data. The participating centers provided consent for data sharing facilitated by the European Genome-Phenome Archive (EGA) and RD-Connect (\url{https://platform.rd-connect.eu/}), and we advocate that adopting such an approach will enable future matchmaking between extremely rare cases, such as \textit{BVES}-related myopathy\textsuperscript{34} or LGMD R21 \textit{PGLUTI}-related.\textsuperscript{35} In addition, thanks to the large cohort size and standardized deep phenotypic data, we were able to expand the clinical and mutational spectrum of known causative genes, such as \textit{TRIM32},\textsuperscript{36} \textit{POMK},\textsuperscript{37} \textit{DPM3},\textsuperscript{38} \textit{POMT2},\textsuperscript{39} and other dystroglycanopathies.\textsuperscript{40}

Based on our findings from this large-scale international collaboration, we suggest a new diagnostic approach in the clinic and/or private health providers. Rather than implementing small NGS panel approaches, led by phenotypic clues that can often be misleading due to the high clinical heterogeneity of muscle diseases, patients should be directly referred for exome sequencing. The exome sequencing data of NMD patients of European and Middle Eastern origin should first be promptly analyzed for pathogenic variants in the eight genes most commonly associated with muscle disease in our cohort—\textit{CAPN3}, \textit{DYSF}, \textit{ANOS}, \textit{DMD}, \textit{RYR1}, \textit{TTN}, \textit{COL6A2}, and \textit{SGCA}. This is expected to diagnose over a quarter of individuals. The analysis pipeline should then be extended to include additional NMD genes, enabling a diagnosis in a further quarter of patients. For those patients who remain undiagnosed, their ES data can be further interrogated. Importantly, exome data can be retrospectively and repeatedly analyzed for pathogenic variants in novel disease genes as new discoveries are made, making it a much more cost-effective approach.

\textbf{SUPPLEMENTARY INFORMATION}

The online version of this article (\url{https://doi.org/10.1038/s41436-020-0840-3}) contains supplementary material, which is available to authorized users.

\textbf{ACKNOWLEDGEMENTS}

We thank the patients for donating their tissue samples. MYO-SEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, Samantha J. Brazzo Foundation, LGMD2D Foundation and Kurt-Peter Foundation, Muscular Dystrophy UK, and Coalition to Cure Calpain 3. Analysis was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung, and Blood Institute grant UM1 HG008900, and in part by National Human Genome Research Institute grant R01 HG009141.

\textbf{DISCLOSURE}

D.G.M. is a founder with equity in Goldfinch Bio, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Merck, Pfizer, and Sanofi Genzyme. V.S. is or has been a principal investigator for trials sponsored by Sanofi Genzyme, GSK, Prosensa/Biomarin, IonisPharmaceuticals, and Sarepta. He has received speaker honoraria from Sanofi Genzyme. He is or has been on advisory boards for Acceleron Pharma, Audentes Therapeutics, Biomarin, Bristol-Myer Squibb, Italfarmaco S.p.A., Nicox, Pfizer, Sanofi Genzyme, Santhera, Sarepta Therapeutics, Summit Therapeutics, Tivorsan, and TrophyNOD. The other authors declare no conflicts of interest.

\textbf{Publisher’s note} Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
REFERENCES

1. Mercure C, Muntoni F. Muscular dystrophies. Lancet. 2013;381:845–860.
2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part I: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.
3. Bonne G, Rivier F, Hamroun D. The 2018 version of the gene table of monogenic neuromuscular disorders (nucleus genome). Neuromuscul Disord. 2017;27:1152–1183.
4. Harris E, Laval S, Hudson J, et al. Undiagnosed genetic muscle disease in the north of England: an in depth phenotype analysis. PLoS Curr. 2013;5:
https://doi.org/10.1371/currents.mtd.37840ac6765e7252945e7c5f5140487e.
5. Cramer SE, Cropperton AG, Hershman SG, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med. 2012;4:118ra10.
6. Savarese M, Di Fruscio G, Torella A, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. Neurology. 2016;87:71–76.
7. Nallamilli BR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. 2018;5:1574–1587.
8. Peric S, Glumac JN, Topf A, et al. A novel recessive TTN founder variant is a common cause of distal myopathy in the Serbian population. Eur J Hum Genet. 2017;25:572–581.
9. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291.
10. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
11. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007;17:1665–1674.
12. Larson JL, Silver AJ, Chan D, et al. Validation of a high resolution NGS method for detecting spinal muscular atrophy carriers among phase 3 participants in the 1000 Genomes Project. BMC Med Genet. 2015;16:100.
13. Dominov JA, Uyan O, McKenna-Yasek D, et al. Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. Ann Clin Transl Neurol. 2019;6:642–654.
14. Cummings BB, Marshall JL, Tukiainen T, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med. 2017;9 eaal5209.
15. Sarkozy A, Hicks D, Hudson J, et al. ANOS gene analysis in a large cohort of patients with anotocinaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation. Hum Mutat. 2013;34:1111–1118.
16. De Ridder W, Azmi A, Clemen CS, et al. Multisystem proteinopathy due to mutations in the PYROXD1 gene. J Neurol Neurosurg Psychiatry. 2019;90:3913.
17. van der Zee J, Pirici D, Van Langenhove T, et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology. 2009;73:626–632.
18. Schindler RF, Scotton C, Zhang J, et al. POPDC1(S201F) causes muscular dystrophy and arthromyopathy by affecting protein trafficking. J Clin Invest. 2016;126:239–253.
19. Servian-Morilla E, Takeuchi H, Lee TV, et al. A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss. EMBO Mol Med. 2016;8:1289–1309.
20. O’Grady GL, Best HA, Szatle ET, et al. Variants in the oxidoreductase PYROXD1 gene cause the Hoyeraal-Hreidarsson syndrome. Am J Hum Genet. 2016;99:1086–1105.
21. Gonzalez-Quereda L, Gallardo E, Topf A, et al. A new mutation of the SCGA gene is the cause of a late onset mild phenotype limb girdle muscular dystrophy type 2D with axial involvement. Neuromuscul Disord. 2018;28:633–638.
22. Johnson K, Topf A, Bertoli M, et al. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness. Orphanet J Rare Dis. 2017;12:173.
23. Fanin M, Angelini C. Protein and genetic diagnosis of limb girdle muscular dystrophy type 2A: the yield and the pitfalls. Muscle Nerve. 2015;52:163–173.
24. Xie Z, Hou Y, Yu M, et al. Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients. Orphanet J Rare Dis. 2019;14:43.
25. Bevilacqua JA, Guecaimburu Ehulete MDR, Perna A, et al. The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease. Orphanet J Rare Dis. 2020;15:11.
26. Monies D, Ahindi BN, Almuhaizea MA, et al. A first-line diagnostic assay for limb-girdle muscular dystrophy and other myopathies. Hum Genomics. 2016;10:32.
27. Vissing J, Johnson K, Topf A, et al. POPDC3 gene variants associate with a new form of limb girdle muscular dystrophy. Ann Neurol. 2019;86:832–843.
28. Zenagui R, Lacourt D, Pegeot H, et al. A reliable targeted next-generation sequencing strategy for diagnosis of myopathies and muscular dystrophies, especially for the giant titin and nebulin genes. J Mol Diagn. 2018;20:533–549.
29. Harris E, Topf A, Barresi R, et al. Exome sequences versus sequential gene testing in the UK highly specialised service for limb girdle muscular dystrophy. Orphanet J Rare Dis. 2017;12:151.
30. Zhao M, Maani N, Dowling JJ. DNM2 as cause of, and modifier for, human neuromuscular disease. Neurotherapeutics. 2018;15:966–975.
31. Pang AW, MacDonald JR, Pinto D, et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol. 2010;11:R52.
32. Lee Y, Jonson PH, Sarparanta J, et al. TIA1 variant drives myogenic differentiation in multisystem proteinopathy with QSTM1 mutations. J Clin Invest. 2018;128:1164–1177.
33. Andrade RC, Nevado J, de Faria Domingues de Lima MA, et al. Segmental uniparental isodisomy of chromosome 6 causing transient diabetes mellitus and merosin-deficient congenital muscular dystrophy. Am J Med Genet A. 2014;164A:2908–2913.
34. De Ridder W, Nelson I, Asselbergh B, et al. Muscular dystrophy with arrhythmia caused by loss-of-function mutations in BVE5. Neurol Genet. 2019;5:e321.
35. Servian-Morilla E, Cabrera-Serrano M, Johnson K, et al. POGLUT1 biallelic mutations cause myopathy with reduced satellite cells, alpha-dystroglycan hypoglycosylation and a distinctive radiological pattern. Acta Neuropathol. 2020;139:565–582.
36. Johnson K, De Ridder W, Topf A, et al. Extending the clinical and mutational spectrum of TRIM52-related myopathies in a non-Hutterite population. J Neurol Neurosurg Psychiatry. 2019;90:490–493.
37. Strang-Karlsson S, Johnson K, Topf A, et al. A novel compound heterozygous mutation in the POMK gene causing limb-girdle muscular dystrophy-dystroglycanopathy in a sib pair. Neuromuscul Disord. 2018;28:614–618.
38. Van den Bergh PYK, Sznajer Y, Van Parys W, et al. A homozygous DPM3 mutation in a patient with alpha-dystroglycan-related limb girdle muscular dystrophy. Neuromuscul Disord. 2017;27:1043–1046.
39. Onodera S, Johnson K, Topf A, et al. Beta-galactosidase generated muscular dystrophy due to mutations in POMT2. J Neurol Neurosurg Psychiatry. 2018;89:506–512.
40. Johnson K, Bertoli M, Phillips L, et al. Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness. Skelet Muscle. 2018;8:223.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if you modified the material. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The MYO-SEQ consortium

Ela Akay1,7, Jorge Alonso-Pérez5, Jonathan Baets6,7, Nina Barisic8, Alexandra Bastian9,10, Sabine Borell11, Teodora Chamova12, Kristl Claeys13, Jaume Colomer14, Sandra Coppens15,16, Nicolas Deconinck17,18, Willem de Ridder6,7, Jordi Díaz-Manera5,19, Cristina Domínguez-González19,20, Alexis Duncan21, Hacer Durmus22, Nagia A. Fahmy23, Maria Elena Farrugia24, Roberto Fernández-Torrón25,26, Lidia Gonzalez-Quereda19,28, Jana Haberlova29, Maja von der Hagen30, Andreas Hahn31, Antonio Jakovčević32, Ivonne Jerico Pascual33, Solange Kapetanovic34, Viktorija Kenina35,36, Heike Kölbl38, Anna Kostera-Pruszczyk39, Richta Kulshrestha40, Jaana Lähdetie41, Mahsa Layegh42, Cheryl Longman21, Adolfo López de Munain25,26,43, Wolfgang Loscher44, Anna Lusakowska39, Paul Maddison4, Armelle Magot45, Anirban Majumdar46, Pilar Marti19,47,48, Amaia Martínez Arroyo49, Radim Mazanec29, Sandra Mercier45, Tiziana Mongini50, Nuria Muelas19,47,48, Andrés Nascimento40, Shahriar Nafissi42, Shirin Omidii42, Carlos Ortez14, Stéphanie Paquay51, Yann Pereon45, Stojan Perić52, Valentina Ponzalino50, Vidosava Rakočević-Stojanovic52, Gauthier Remiche53, Ana Tanev12, Ivailo Tournev12,63, Peter Van den Bergh51, Vinciane Van Parijs51, Juan Vilchez19,47,48, Katharina Vill64, John Vissing65, Carina Wallgren-Pettersson60,66, Julia Wanschitz44, Tracey Willis40, Nanna Witting65 and Miren Zulaica25,26

1 John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 2Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA; 3Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA; 4Present address: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 5Present address: Northern Genetics Service, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK; 6Present address: Department of Genetics, Yale University School of Medicine, New Haven, CT, USA; 7Present address: Directorate-General for Research and Innovation, Directorate E, Unit E2 Combatting Diseases, Brussels, Belgium; 8Present address: Centre for Population Genomics, Garvan Institute of Medical Research, Sydney, Australia; 9Present address: Centre for Population Genomics, Murdoch Children’s Research Institute, Melbourne, Australia.

The MYO-SEQ consortium

Ana Töpf, PhD4, Katherine Johnson, PhD1,67, Adam Bates, MSc1, Lauren Phillips, BSc1, Katherine R. Chao, BSc2,3, Eleina M. England, MSc2,3, Kristen M. Laricchia, MSc2,3, Thomas Mullen, PhD2,3, Elise Valkanas, BA2,3, Liwen Xu, MD, MPhil2,3, Marta Bertoli, MD1,68, Alison Blain, PhD1, Ana B. Casasús, MSc1, Jennifer Duff, PhD1, Magdalena Mroczek, MD1, Sabine Specht, MD1, Monkol Lek, PhD2,3,69, Monica Ensini, PhD1,70, Daniel G. MacArthur, PhD2,3,71,72, the MYO-SEQ consortium and Volker Straub, MD1

4Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK; 5Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerpen, Belgium; 7Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium; 8Clinical Medical Centre Zagreb, University of Zagreb, Zagreb Medical School, Zagreb, Republic of Croatia; 9Colentina University Hospital-CDPC-CCC, Bucharest, Romania; 10University of Medicine and Pharmacy Carol Davila Bucharest, Faculty of Dental Medicine, Bucharest, Romania; 11Department of Neuropediatrics, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 12Department of Neurology, UMHAT, Alexandrovska Medical University, Sofia, Bulgaria; 13Department of Neurology, University Hospitals Leuven, and Laboratory for Muscle Diseases and Neuropathies, KU Leuven, Leuven, Belgium; 14Unitat de Patologia Neuromuscular, Servei de Neurologia, Hospital Sant Joan de Deu, ISCIII, CIBERER, Barcelona, Spain; 15Department of Pediatric Neurology, Neuromuscular Reference Center, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; 16Department of Pediatric Neurology, Neuromuscular Reference Center, Hôpital Universitaire des Enfants Reines Fabiola, Université Libre de Bruxelles, Brussels, Belgium; 17Neuromuscular Reference Center, Universitair Ziekenhuis Gent (UZ Gent), Ghent, Belgium; 18Neuromuscular Reference Center, Hôpital Universitaire des Enfants Reines Fabiola (HUDERF), ULB, Brussels, Belgium; 19Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain; 20Instituto de Investigación Hospital 12 de Octubre Centro de Actividades Ambulatorias, Madrid, Spain; 21West of Scotland Centre for Genomic Medicine, University of Glasgow, Glasgow, Scotland; 22Neuromuscular Reference Centre, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; 23Department of Neuroplasticity, University Hospitals Leuven and Laboratory for Muscle Diseases and Neuropathies, KU Leuven, Leuven, Belgium; 24Department of Neurology, University of Padua, Padua, Italy; 25Department of Neurology, University of Barcelona, Barcelona, Spain; 26Department of Neurology, Vall d’Hebron University Hospital, Barcelona, Spain; 27Clinical Research Unit, Institute of Medical Genetics, University of Auckland, Auckland, New Zealand; 28Department of Human Genetics, University of Padua, Padua, Italy; 29Department of Medical and Molecular Genetics, University of Lausanne, Lausanne, Switzerland; 30Department of Neurology, University of Antwerp, Antwerpen, Belgium; 31Department of Neurology, University of Zurich, Zurich, Switzerland; 32Department of Neurology, University of Zagreb, Zagreb, Croatia; 33Department of Neurology, University of Copenhagen, Copenhagen, Denmark; 34Department of Neurology, University of Ljubljana, Ljubljana, Slovenia; 35Department of Neurology, Université de Genève, Genève, Switzerland; 36Department of Neurology, University of Freiburg, Freiburg, Germany; 37Department of Neurology, University of Innsbruck, Innsbruck, Austria; 38Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands; 39Department of Neurology, Pirovac University Hospital, Pirovac, Croatia; 40Department of Neurology, The Royal Melbourne Hospital, Parkville, Australia; 41Department of Neurology, University of Maryland School of Medicine, Baltimore, USA; 42Department of Neurology, University of Liège, Liège, Belgium; 43Department of Neurology, University of Murcia, Murcia, Spain; 44Department of Neurology, University of Antwerp, Antwerp, Belgium; 45Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands; 46Department of Clinical Neurology, Lappeenranta University of Technology, Lappeenranta, Finland; 47Institute of Genomics and Proteomics, Juan de la Cierva Centre for Biomedical Research, Madrid, Spain; 48University of The Basque Country UPV/EHU, Bilbao, Spain; 49Department of Neurology, University Hospital La Fe, Valencia, Spain; 50Department of Neurology, University Hospital Niguarda, Milan, Italy; 51Department of Neurology, University of New South Wales, Sydney, Australia; 52Department of Neurology, University Hospitals Leuven, and Laboratory for Muscle Diseases and Neuropathies, KU Leuven, Leuven, Belgium; 53Department of Neurology, University of Amsterdam, Amsterdam, The Netherlands; 54Department of Neurology, University of Iceland, Reykjavik, Iceland; 55Department of Neurology, University of Valencia, Valencia, Spain; 56Department of Neurology, University of Barcelona, Barcelona, Spain; 57Department of Neurology, Maastricht University, Maastricht, The Netherlands; 58Department of Neurology, Children’s Hospital Zagreb, University of Zagreb, Zagreb, Croatia; 59Department of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 60Department of Neurology, Uppsala University, Uppsala, Sweden; 61Department of Neurology, Karolinska Institutet, Stockholm, Sweden; 62Department of Neurology, New York University School of Medicine, New York, USA; 63Department of Neurology, Ghent University Hospital, Ghent, Belgium; 64Department of Neurology, University of Cape Town, Cape Town, South Africa; 65Department of Neurology, University of Melbourne, Melbourne, Australia; 66Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; 67Present address: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 68Present address: Northern Genetics Service, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK; 69Present address: Department of Genetics, Yale University School of Medicine, New Haven, CT, USA; 70Present address: Directorate-General for Research and Innovation, Directorate E, Unit E2 Combatting Diseases, Brussels, Belgium; 71Present address: Centre for Population Genomics, Garvan Institute of Medical Research, Sydney, Australia; 72Present address: Centre for Population Genomics, Murdoch Children’s Research Institute, Melbourne, Australia.
